Lastly, Sendur et al. [63] reviewed 164 patients (N = 108 with 9-week treatment, N = 56 with 52-week treatment) on adjuvant monotherapy trastuzumab for HER2 breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.